The present disclosure encompasses QS-21-based structurally-defined adjuvants to address the need for stronger, safer, and easier-to-access adjuvants. The new compositions can provide tools for addressing long-standing mechanistic questions concerning saponin immune-potentiation through structure-activity-relationship (SAR) studies. Most advantageously, the compounds of the disclosure may be formulated into pharmaceutically acceptable compositions, including vaccines that may be delivered to a subject human or animal subject. The compounds can then act as, for example, an adjuvant to augment an immunological response to a vaccine immunogen.
本公开涵盖基于QS-21的结构定义佐剂,以解决更强、更安全、更易获得的佐剂需求。新的组合物可以提供工具来通过结构活性关系(
SAR)研究解决长期存在的
皂苷免疫激活机制问题。最有优势的是,本公开的化合物可以制成药学上可接受的组合物,包括可以提供给人或动物的疫苗。然后,这些化合物可以作为佐剂,例如增强对疫苗免疫原的免疫反应。